

Post-Pandemic Dental Practice: COVID-19, Oral Health & Infection Control



Course Author: Maria L. Geisinger, DDS, MS

CE Credits: 2 hours

Intended Audience: Dentists, Dental Hygienists, Dental Assistants, Dental Students, Dental Hygiene Students, Dental Assisting Students

Date Course Online: 03/15/2024

Last Revision Date: NA

Course Expiration Date: 03/14/2027

Cost: Free

Method: Self-instructional

AGD Subject Code(s): 148, 10, 490

Online Course: www.dentalcare.com/en-us/ce-courses/ce665

Disclaimers:

- P&G is providing these resource materials to dental professionals. We do not own this content nor are we responsible for any material herein.
- Participants must always be aware of the hazards of using limited knowledge in integrating new techniques or procedures into their practice. Only sound evidence-based dentistry should be used in patient therapy.

Conflict of Interest Disclosure Statement

- Dr. Geisinger reports no conflicts of interest associated with this course. She has no relevant financial relationships to disclose.

Short Description

This course seeks to discuss the evolution of infection control in the dental office and our understanding of the interactions between oral disease and COVID-19 infection.

Course Contents

- Overview
- Learning Objectives
- Introduction
- COVID-19 Impact on Dental Practice Infection Control
 - Enhanced Infection Control Practices
 - Screening Mechanisms
 - Adjunctive Infection Control Methods
- Oral Manifestations of COVID-19
- Periodontal Disease Impact and COVID-19 Severity
- COVID-19 and Dental Practice
- Gaps in our Knowledge Regarding COVID-19 and Oral Health
- Summary
- References / Additional Resources

Overview

The COVID-19 pandemic represented a paradigm shift in dental care delivery and risk mitigation within the dental practice. As we move forward as a profession, reflecting on the impact that the COVID-19 pandemic has had on our practices and what we have learned regarding the importance of oral health for outcomes with high consequence infectious diseases (HCIDs) allows us to better serve our patients and to communicate how essential dental care is to overall wellness. This course will review the impact of the COVID-19 pandemic on the field of dentistry in the US and globally. We will review the expansion of our knowledge base regarding in-office dental infectious control, including emerging data on aerosol transmission of disease within dental practices. We will also assess the emerging data regarding the long- and short-term oral manifestations of COVID-19 infection and the impact of periodontal health and inflammation of COVID-19 symptom severity.

Learning Objectives

Upon completion of this course, the dental professional should be able to:

- Assess enhanced infection control practices based upon expanded scientific knowledge after the COVID-19 pandemic.
- Review data regarding short and long-term oral manifestations of COVID-19 and the potential impact of COVID-19 related stress on patients' oral health.

- Assess the emerging science regarding periodontal disease and oral inflammation and COVID-19 disease severity.
- Identify gaps in our knowledge and further research questions regarding the impact of COVID-19 for the dental field.

Introduction

In 2019, a novel β -coronavirus [severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)] causing severe and potentially fatal pneumonia was identified in Wuhan city, Hubei province, China.¹⁻³ This virus and the subsequent illness, coronavirus disease 2019 (COVID-19) initiated a pandemic.⁴ Clinical symptoms of acute SARS-CoV-2 infection in a patient without immunity include fever, dry cough, myalgia, fatigue, and pneumonia with abnormal chest CT. Less commonly observed symptoms include sputum production, headache, hemoptysis, and diarrhea.⁵⁻⁷ Further, heterogeneity in symptom frequency have been demonstrated with shifts in symptoms based upon different variants.⁸ The person-to-person transmission of SARS-CoV-2 includes direct transmission, such as cough, sneeze, saliva and other droplet inhalation transmission, distant airborne transmission of droplet nuclei, and contact transmission, such as the contact with oral, nasal, and eye mucous membranes.⁹⁻¹¹ Fomite transmission has also been proposed, although it is likely a very minor transmission pathway.¹¹

Prior to the COVID-19 pandemic, infection control in the dental office focused on bloodborne pathogens and Standard and Transmission based precautions limiting exposure to bodily fluids and other potentially infectious materials.¹²⁻¹⁷ There are three categories of Transmission-based Precautions: contact precaution, droplet precautions, and airborne precautions associated with droplet nuclei.¹⁵⁻¹⁷ During the initial days of the pandemic, the airborne transmission of SARS-CoV-2 was believed to pose particular issues for delivery of safe dental care. Dental health care personnel (DHCP) and their patients were presumed to be at increased occupational risk associated with aerosols in the dental office due to the frequency of close, personal face-to-face communication and exposure to saliva,

blood, and other body fluids, and—indirectly—by the handling of sharp instruments and touching contaminated dental surfaces.¹⁸⁻²¹

It has been well-established that delivery of many dental procedures results in the generation of aerosols, which could result in the airborne spread of infectious material and the perception of routes of transmission in dentistry have been altered by COVID-19 and the subsequent practices of enhanced infectious control during and following the pandemic.^{22,23} Recent evidence has also shown that there may be a link between oral health and COVID-19 infection. Given these considerations, this course seeks to review the evidence on infectious diseases and oral and overall health that was gleaned during and after the COVID-19 pandemic and the implications on the provision of dental care.

COVID-19 Impact on Dental Practice Infection Control

The COVID-19 pandemic has thrust infection control practices into the forefront and has highlighted the need for review of safety protocols and practices to ensure optimal working environments for patients and healthcare workers alike. In dentistry, the exposure of dental healthcare professionals and patients to both airborne and bloodborne pathogens was identified as a potential risk from early periods in the pandemic and enhanced infection control practices were sought to mitigate risks of exposure and infection during the provision of dental care.²³⁻²⁶ After the initial emergence of SARS-CoV-2 in China in 2019, many governmental bodies mandated service limitations and/or shut-downs for healthcare workers, including those providing dental care.^{16,17,27} Further, both pharmaceutical and nonpharmaceutical measures were put into place to limit disease transmission and severity, including quarantine, physical distancing, hygiene measures and vaccination protocols.²⁸ Within the dental setting, national recommendations for dental healthcare professionals included enhancements to infection control practices like enhanced personal protective equipment (PPE), surface decontamination,

post-appointment surveillance, and patient assessment and triage.²⁹

Due to the droplet and airborne transmission risk of SARS-CoV-2, enhanced infection control practices were recommended as interim protocols, many of which have now become standard practice in many dental offices.^{9,30,31} Studies have shown that COVID-19 did result in statistically significant differences in the use of protective barriers such as hair covers and eye protection/face shields and disinfection practices.³² Furthermore, despite concerns early in the pandemic, data indicate that with the use of such enhanced infection control practices, delivery of dentistry resulted in very low transmission rates.³³⁻³⁴ These findings further highlight the expertise of dental healthcare professionals in infection control practices and the willingness of dental healthcare professionals to adapt to improve safety for their patients and colleagues.

Enhanced Infection Control Practices

In 2016, the United States Centers for Disease Control and Prevention (CDC) established “basic expectations for safe care” in dental practice settings.³⁵ These expectations included a set of standard precautions, including hand hygiene, PPE, respiratory etiquette, safe injection practices, appropriate storage and handling of instruments, instrument sterilization, and disinfection of practice environments/surfaces.³⁵ Further, the CDC recommended additional transmission-based precautions, such as identification of infectious patients, contact precautions, droplet and aerosol precautions.³⁵ The COVID-19 based precautions for dental settings from the CDC and the American Dental Association built upon these protocols and incorporate engineering and administrative controls (Figure 1).^{36,37} In response to the COVID-19 pandemic, awareness of aerosols within the dental office came into sharp focus and practices to reduce infectious aerosols were employed. Such practices include ventilation and practice layout, extraoral suction, advanced respirators and/or mask filtration, and pre-operative patient screening.³⁷ A survey deployed during the pandemic demonstrated high levels of adherence to enhanced infection control practices by dentists in their practice over a six-

month period.³³ Longer studies conducted in the same manner also demonstrated low infection risks and high rates of adherence to enhanced infection control practices.³⁴ It is also likely that many of these practices have been incorporated into standard infection control practices post-pandemic.



Figure 1. Considerations for infection control in dentistry.

Current recommendations from the CDC and regional/state dental boards include risk-based assessment of community infection rates and individual patient and practitioner risk assessments to reduce COVID-19 transmission in the dental office. The CDC recommends routine infection prevention and control (IPC) practices, including remaining up-to-date with all recommended COVID-19 vaccine doses. The following current best-practices to address continued risk for COVID-19 infection for healthcare professionals:²⁹

- **Establish a Process to Identify and Manage Individuals with Suspected or Confirmed SARS-CoV-2 infection:** Visual alerts in strategic places throughout healthcare facilities can alert patients and healthcare professionals to the infection control practices at the facility. Individuals should

be informed of the policies if they have had a positive test for SARS-CoV-2, symptoms of COVID-19, or close contact with an individual with SARS-CoV-2 infection.

- **Implement Source Control Measures:** This includes the use of well-fitting facemasks or respirators to reduce the spread of respiratory secretions
- **Implement Universal Use of Personal Protective Equipment for HCP:** This includes barrier protection for Standard and/or Transmission Based Protocols based upon suspected diagnosis. The CDC also notes that as SARS-CoV-2 transmission rates in the community increase, healthcare professionals should consider implementing broader use of respirators and eye protection.
- **Optimize the Use of Engineering Controls and Indoor Air Quality:** These include proper ventilation, physical barriers at reception/triage locations, appropriate disinfection,³⁸ intraprocedural evacuation as well as avoidance of crowded communal areas.
- **Protocols to Address COVID-19 Infection in Practitioners:** Ongoing self-monitoring and appropriate quarantine/infection prevention and control practices should be established a priori for all staff within the dental healthcare facility.

It should also be noted that the implementation and utilization of such protocols is currently being revised by OSHA and the CDC and dental healthcare workers are encouraged to regularly review all of the following:³⁹

- The *level of ongoing community transmission* of COVID-19 in their community. The CDC continues to monitor community levels of COVID transmission and track those in their COVID Risk assessment tool.
- The *phase of reopening* (if applicable) the community in which the dental practice is located has entered.
- The *risk to dental practitioners and support staff* of being exposed to sources of SARS-CoV-2, including suspected and confirmed COVID-19 cases and people who are infected with SARS-CoV-2 but do not have signs and/or symptoms of COVID-19 (but who may be able to spread the virus to others without knowing it).

- The availability and ability of the employer to implement controls to protect workers from exposure to sources of SARS-CoV-2.

Screening Mechanisms

Every practice needs to have a daily production. The implementation of teledentistry practices during the pandemic allowed for pre-procedural assessments of patient symptoms without an in-person interaction between patient and dental healthcare professional. Such pre-procedural assessments allow dental healthcare professionals to assess patients for exposure and infectious symptoms prior to delivery of dental care and may identify high-risk patients and reduce exposure for dental healthcare professionals. The objective of such screening allows dental healthcare professionals to limit or select the patients who have access to the dental clinical environment. Further, evidence suggests that utilization of teledentistry increased significantly during and after the COVID-19 pandemic.^{39,40} It is notable that social influences positively impacted dentists' willingness to engage in teledentistry and the increase in the utilization during COVID-19 may result in long-term shifts in dental consultation delivery via teledentistry services.⁴¹ This could result in triage or delivery of palliative care for patients with urgent/emergent leads who may be at higher risk of infectious spread and postponement of elective procedures in high-risk individuals.²³ It should be noted that the application of teledentistry varies by localities and dental healthcare providers should confirm with their regulatory bodies, including federal, state, and/or other regulatory boards to determine allowable application in their area.

Adjunctive Infection Control Methods

In addition to enhanced methods to reduce aerosols, dental healthcare professionals should implement additional infection control measures, including vaccination protocols and administrative and engineering controls within the dental office. Recommendations from the CDC include administrative measures and education for individuals in dentistry. The occupational safety and health administration (OSHA) has created a hierarchy of controls to address workplace health and safety, including in healthcare settings: Risk elimination, Engineering controls, Administrative practices, and PPE (Figure 2).⁴²



Figure 2. OSHA's Hierarchy of Infection Controls in Healthcare Environments

Recommendations for infection control in a dental office include:

1. Develop and maintain infection prevention and occupational health programs.
2. Provide supplies necessary for adherence to Standard Precautions (e.g., hand hygiene products, safer devices to reduce percutaneous injuries, personal protective equipment).
3. Assign at least one individual trained in infection prevention responsibility for coordinating an infection control program.
4. Develop and maintain written infection prevention policies and procedures appropriate for the services provided by the facility and based on evidence-based guidelines, regulations, or standards.
5. Facility has system for early detection and management of potentially infectious persons at initial points of patient encounter.
6. Provide job or task-specific infection prevention education and training to all DHCP. This includes those employed by outside agencies and available by contract or on a volunteer basis to the facility.
7. Provide training on principles of both DHCP safety and patient safety.
8. Provide training during orientation and at regular intervals (e.g., annually).
9. Maintain training records according to state and federal requirements.

Oral Manifestations of COVID-19

It was noted early in the pandemic that early signs of COVID-19 infection included dysosmia and dysgeusia.^{43,44} It is also known that SARS-CoV-2, as well as SARS-CoV-1 and MERS, enter cells through binding to angiotensin-converting enzyme 2 receptor (ACE2), which is highly expressed in many cell types and, of particular interest to dental healthcare professionals, in oral mucosa and salivary glands. In particular ACE2 is expressed with higher density on the tongue dorsum and major and minor salivary glands in the buccal mucosa and palate.⁴³⁻⁴⁸ Further, case reports published early in the pandemic described a myriad of oral manifestations of COVID-19 infection including: oral ulcerations, mucosal erosion, bullae, vesicle formation, pustules, fissured or depapillated tongue, macules, papules, increased and/or decreased pigmentation, halitosis, leukoplakia, hemorrhagic crust, oral tissue necrosis, petechiae, edema, erythema, and spontaneous bleeding.⁴⁵⁻⁴⁹ It should also be noted that post-infection xerostomia has also been noted in a significant number of cases, even after resolution of other acute COVID-19 symptoms.⁴⁸

While reports in the current literature have a high level of heterogeneity, findings indicate that the prevalence of oral lesions was approximately 33% and aphthous lesions were found in approximately 10% of cases.⁴⁸ Multiple suggested diagnoses have been proposed for oral lesions associated with COVID-19 to include aphthous stomatitis, herpetiform lesions, candidiasis, vasculitis, Kawasaki-like, erythema multiforme-like, mucositis, necrotizing periodontal disease, angina bullosa-like, angular cheilitis, atypical Sweet syndrome, and Melkerson-Rosenthal syndrome.⁴⁵ Reported oral lesions were symptomatic in approximately 68% of cases and older individuals and those who presented with more severe systemic COVID-19 symptoms demonstrated more severe and widespread oral lesions.⁴⁵ Oral health measures, including poor oral hygiene and pre-existing oral disease, were also associated with higher rates and increased severity of COVID-19 associated oral lesions.^{43,47,48} Current case reports do not allow for evaluation of all underlying etiologies for these oral lesions, including direct and/or indirect causation by

the SARS-CoV-2 virus, secondary opportunistic infections, or coincidental outcomes.⁵⁰

Dental healthcare professionals should be aware that oral lesions may present as prodromal and/or early signs of COVID infection (Figure 3). In the case pictured below, an afebrile patient presenting with cough also noted oral lesions, dysgeusia and discomfort associated with the affected oral areas. Antigen COVID-19 tests on the day of presentation with oral lesions resulted in a negative test result, but PCR test performed the same day resulted in a positive test result that was available 24 hours after nasal swab testing. Identification of such lesions in combination with monitoring for other COVID-19 symptoms could result in earlier testing and/or referral to reduce asymptomatic/early SARS-CoV-2 spread. Additionally, a focus on establishing and promoting oral health as a mechanism to impact overall health is a critical learning point from the findings related to COVID-19 and oral health.




Figure 3. Oral Lesion Presenting Prior to frank COVID-19 Infection (Photo Courtesy of Dr. Mengyi (Lisa) Shi-Franks)

Periodontal Disease Impact and COVID-19 Severity

It is well-established that periodontal diseases are infectious and inflammatory and that the inflammatory burden of periodontal diseases can impact systemic health and create a hyperinflammatory state.⁵¹⁻⁵³ During the COVID-19 pandemic, a puzzling aspect of disease presentation was the heterogeneity of symptoms experienced by infected patients with presentations ranging from asymptomatic infections to severe disease resulting in

hospitalization or death.^{54,55} Underlying systemic disease and hyperinflammatory conditions, including obesity, cardiovascular disease, diabetes mellitus and tobacco use, were associated with increased morbidity and mortality from COVID-19 infections.⁵⁶⁻⁵⁹ Much of the link between such diseases as COVID-19 severity has been attributed to the impact of a “cytokine storm” mounted by host defenses during the course of the infection.⁵⁷ Because of the inflammatory nature of both periodontitis and severe COVID-19, multiple investigations have focused on the impact of periodontitis on COVID-19 disease severity.⁶⁰⁻⁷⁰

Common risk factors have been associated with both periodontitis and severe COVID-19, including smoking, increased age, obesity, diabetes mellitus, and cardiovascular disease.^{56,61} It was initially unclear if these common comorbidities were responsible for any association between periodontitis and COVID-19 severity or if specific pathophysiology linked periodontitis and COVID-19 severity.^{65,66} Studies conducted early in the pandemic demonstrated that moderate to severe periodontitis (stage 2-4) was significantly associated with an increased risk of COVID-19 complications and mortality and that radiographic alveolar bone loss was associated with increased COVID-19 seropositivity and disease severity.^{67,68}

Mechanisms for this association have been proposed to include: 1) the periodontal pocket as a reservoir for infectious material and/or micro-RNAs associated with upregulating ACE2 expression, 2) periodontitis as a contributor to systemic inflammation and thus the “cytokine storm”, and 3) periodontitis resulting increased bacterial aspiration into the lungs as a contributor to secondary pneumonias.⁶⁵

Periodontal Pockets as Reservoirs of Disease

Cadaveric biopsies in COVID-19 patients have demonstrated SARS-CoV-2 present within periodontal tissues.⁶⁹ As periodontal disease is associated with ulcerated pocket epithelium,⁵² the presence of periodontitis could represent a pathway for entry of SARS-CoV-2 into the systemic circulation, either directly through ulcerated epithelium or via uptake into

cells through ACE2 receptors, which may be upregulated in the presence of periodontal pathogens (e.g. *F. nucleatum*) and micro-RNAs 146a and 155, which are increased in the periodontal pocket at sites with periodontitis.⁷⁰⁻⁷²

Periodontitis and Systemic Inflammation

Systemic inflammation in periodontitis is characterized by high levels of pro-inflammatory cytokines and C-reactive protein.^{73,74} Periodontitis has also been shown to prime the immune response to react to an infectious challenge with an exaggerated innate response through activation of polymorphonuclear leukocytes (PMNs) that results in their chemotaxis and activation in response to local and systemic triggers.⁷⁵ The contribution of pro-inflammatory cytokines, including those cytokines associated with periodontitis, to the “cytokine storm” which is associated with significant morbidity and mortality after COVID-19 infection could indicate that the systemic inflammation associated with periodontitis could help induce and/or potentiate this cytokine activity.⁷⁶⁻⁷⁹ PMNs with an activated phenotype have also been noted in COVID-19 patients, resulting in increased oxidative bursts and phagocytosis which contribute to the acute respiratory distress syndrome. These activated PMNs may be upregulated or primed by pre-existing periodontitis.⁷⁹

Periodontal Bacterial Aspiration

The oral microbiome has been connected to pneumonias and other respiratory diseases.⁸⁰⁻⁸¹ This connection is especially pronounced in individuals with suboptimal oral hygiene, periodontitis, immune dysfunction and in nosocomial settings.⁶⁰ In such cases the oral cavity can serve as a reservoir for respiratory pathogens.⁸²⁻⁸⁴ Because the oral cavity has been demonstrated to be a niche for SARS-CoV-2, viral seeding through aspiration along with other oral pathogens may also serve to enhance severity of COVID-19 or potentiate secondary pneumonias.⁶¹ Further, the combination of periodontopathogenic bacteria which may upregulate ACE2 receptors could also enhance patients’ susceptibility to SARS-CoV-2 infections.⁷⁰⁻⁷² It has also been observed that opportunistic oral pathogens,

Capnocytophaga and Veillonella can be present in pulmonary tissues and fluids of individuals with COVID-19 acute respiratory distress syndrome.⁶⁰ These pathways for secondary infection and/or potentiation of SAR-CoV-2 infection highlight the importance of oral disease prevention and the maintenance of oral health.

COVID-19 and Dental Practice

The COVID-19 pandemic has highlighted the essential role that dental healthcare professionals play in the larger healthcare system and the promotion of patient wellness and disease prevention. Based upon the emerging evidence of the association between periodontitis and COVID-19 infection rates and severity, it has been proposed that periodontal care as a mechanism to establish oral and overall health could play a role in the prevention and management of severe COVID-19 complications.⁸⁵ Enhanced identification of patients with periodontal disease, through regular comprehensive periodontal examinations and health promotion in patients without periodontitis is critical to reduce periodontitis incidence.⁸⁶ Periodontitis prevention through meticulous oral hygiene measures (e.g., professional dental prophylaxis) to remove and/or prevent the formation of a dysbiotic biofilm is appropriate for patients without periodontal attachment loss who are at low risk of disease development.^{86,87} Such care can reduce the incidence of gingivitis and the associated gingival sulcular ulceration which would subsequently prevent viruses and bacteria from the oral cavity from entering the systemic circulation.^{88,89}

In addition to the primary prevention of periodontal diseases, treatment of ongoing periodontal infection and inflammation could decrease systemic inflammation and ameliorate comorbid diseases, such as diabetes mellitus.⁹⁰⁻⁹² The elimination of pathologic periodontal pockets and the niches for bacteria that are formed within them could also reduce those sites as potential reservoirs for oral pathogens and SARS-CoV-2 that could worsen coronavirus-associated pneumonias.

Gaps in our Knowledge Regarding COVID-19 and Oral Health

While current evidence highlights an association between periodontal disease, oral hygiene, and COVID-19 severity as well as a biologic plausibility of the possible nature of this relationship,^{64,93,94} the true mechanisms of action of the interaction between these diseases is not fully elucidated. Currently, there is scarce data from clinical trials and cohort studies to allow for assessment of the interaction between periodontitis and COVID-19. It is imperative that future studies incorporate measures of dental health and oral assessments as a part of risk factor quantification.

It is also currently unknown what the potential long-term effects of COVID-19 infection may be, including the potential for oral diseases. For instance, evidence that has emerged in the last several decades has identified chronic human papilloma virus infection as a causative agent for oropharyngeal cancer.⁹⁵ As more data becomes available about post-acute COVID-19 infection symptomatology and the potential oral manifestations of such so-called “long haul” COVID-19 infections, we may identify other potential oral impacts of COVID-19 infection. Emerging data focused on post-acute COVID-19 syndrome is reported to affect up to 2.5% of infected individuals at 3 months.⁹⁶ Post-acute COVID-19 syndrome demonstrates approximately a 4:1 preponderance for females.⁹⁷ In such individuals more severe symptom presentation has been associated with alterations in taste and smell and it has been established that changes in taste and smell have been associated with a negative impact on mental health and cognitive impairment.^{98,99} As more time post-pandemic unfolds, the scientific community and dental healthcare professionals will learn more about the potential oral implications of COVID-19 infection.¹⁰⁰ Data gathering, including COVID-19 infection and symptoms, is critical to allow dental healthcare professionals to continue to assess oral symptoms and implications of COVID-19 in their patients.

Summary

COVID-19 caused worldwide disruption of delivery of dental care and altered many ways in which dental healthcare professionals approach infection control. Similar to the paradigm shift that occurred after the HIV epidemic and the subsequent focus on prevention of bloodborne pathogen transmission in the dental office, COVID-19 will likely result in substantive changes in infection control methods, particularly as it

pertains aerosol disease transmission in dental practice. The COVID-19 pandemic also served to highlight the oral cavity as a source for uptake of SARS-CoV-2 viral pathogens into the body and the impact of periodontitis and periodontal inflammation on COVID-19 severity. As the impacts of the pandemic continue to be better understood, dental healthcare providers play an integral role in the promotion of overall health through oral health and will help identify and manage the oral impacts of COVID-19 infection.

Course Test Preview

To receive Continuing Education credit for this course, you must complete the online test. Please go to: www.dentalcare.com/en-us/ce-courses/ce665/test

1. Which of the following is the causative infectious agent for COVID-19?

- A. Yersinia pestis
- B. SARS-CoV-1
- C. SARS-CoV-2
- D. BatCoV RaTG13

2. Which of the following is NOT a known method of person-to-person transmission for COVID-19?

- A. Direct transmission through cough, sneeze, or saliva
- B. Contact with mucous membranes
- C. Fomite transmission
- D. Ingestion

3. Consider the following two statements:

Recommendations and requirements for enhanced infection control practices resulted in statistically significant differences in infectious control practices in the dental office.

Such enhancements included increased use of protective barriers like hair covers, but decreased use of eye protection and face shields.

- A. Both statements are true
- B. The first statement is true, the second statement is false
- C. The first statement is false, the second statement is true
- D. Both statements are false

4. In the current post-pandemic environment, which of the following NOT a recommended best practice for infection control and prevention?

- A. Delivery of only emergent dental care
- B. Identification and management of individuals with confirmed or suspected SARS-CoV-2 infection
- C. Implementation of source control measures
- D. Universal use of personal protective equipment for healthcare providers

5. Teledentistry increased significantly during and after the COVID-19 pandemic and engagement in teledentistry was positively impacted by _____.

- A. Technology upgrades in the dental office
- B. Age of dental healthcare professional
- C. Social influences
- D. Community COVID-19 infection rates

6. OSHA has established a hierarchy of infection control practices with the LEAST effective being:

- A. Risk elimination/Risk substitution
- B. Engineering Controls
- C. Administrative and Workplace Practice
- D. Personal Protective Equipment

- 7. SARS-CoV-2 enters human cells through the which cell-surface receptor?**
- A. RANK-ligand
 - B. Protein-tyrosine phosphatase
 - C. Angiotensin converting enzyme 2 (ACE2)
 - D. Interleukin-1
- 8. Aphthous lesions were present as COVID-19 manifestation in approximately ____% of COVID-19 cases.**
- A. 10%
 - B. 25%
 - C. 33%
 - D. 50%
- 9. Poor oral hygiene and pre-existing oral disease has been associated with _____ COVID-associated oral lesions.**
- A. higher rates and increased severity
 - B. lower rates but increased severity
 - C. higher rates but decreased severity
 - D. lower rates and decreased severity
- 10. Which of the following systemic disease/hyperinflammatory conditions is NOT associated with increased morbidity and mortality from COVID-19 infections?**
- A. Obesity
 - B. Chronic liver disease
 - C. Diabetes Mellitus
 - D. Tobacco use
- 11. Consider the following two statements:**
- Periodontitis has been associated with COVID-19 severity in large cohort studies.**
- One mechanism for this association have been proposed to be the contribution of periodontitis to systemic inflammation and the “cytokine storm.”**
- A. Both statements are true
 - B. The first statement is true, the second statement is false
 - C. The first statement is false, the second statement is true
 - D. Both statements are false
- 12. Which of the following is NOT associated with the upregulation of ACE2 receptors and increased viral entry into cells?**
- A. micro-RNA 146a
 - B. micro-RNA 155
 - C. F. nucleatum
 - D. S. mitis
- 13. PMNs with an activated phenotype that demonstrate _____ oxidative bursts and phagocytosis have been noted in COVID-19 positive patients.**
- A. Increased
 - B. Decreased
 - C. Altered
 - D. Unchanged

14. Post-acute COVID-19 syndrome is reported to affect up to _____% of infected individuals at 3 months.

- A. 1%
- B. 2.5%
- C. 5%
- D. 10%

15. Individuals experiencing post-acute COVID-19 syndrome demonstrate a _____ female:male ratio.

- A. 1:1
- B. 2:1
- C. 3:1
- D. 4:1

References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727–733. doi:10.1056/NEJMoa2001017.
2. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern [published correction appears in *Lancet.* 2020 Jan 29;:]. *Lancet.* 2020;395(10223):470–473. doi:10.1016/S0140-6736(20)30185-9.
3. Liu T, Hu J, et al. Transmission Dynamics of 2019 Novel Coronavirus (2019-nCoV). *The Lancet.* 2020 Feb 05. Available at SSRN: doi:10.2139/ssrn.3526307. Accessed December 12, 2023.
4. COVID Data Tracker. Centers for Disease Control and Prevention. Accessed December 12, 2023.
5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in *Lancet.* 2020 Jan 30;:]. *Lancet.* 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5.
6. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. *N Engl J Med.* 2020;NEJMoa2002032. doi:10.1056/NEJMoa2002032.
7. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 Feb 7]. *JAMA.* 2020;e201585. doi:10.1001/jama.2020.1585.
8. SeyedAlinaghi S, Mirzapour P, Dadras O, et al. Characterization of SARS-CoV-2 different variant and related morbidity and mortality: a systematic review. *Eur J Med Res* 2021; 26; 51.
9. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. *Lancet.* 2020;395(10224):e39. doi:10.1016/S0140-6736(20)30313-5.
10. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med.* 2020;382(10):970–971. doi:10.1056/NEJMc2001468.
11. Kirubananthan L, Illuri R, Rajendran R, Chandrasekaran PR. Mechanism and transmission routes of COVID-19. *Environmental and Health Management of Novel Coronavirus Disease (COVID-19).* 2021; 65-88.
12. U.S. Department of Labor, Occupational Safety and Health Administration. 29 CFR Part 1910.1030: Occupational exposure to bloodborne pathogens—OSHA, final rule. *Fed Regist.* 1991;56:64004–64182. Accessed December 12, 2023
13. Garner, JS, The Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals (published correction appears in *Infect Control Hosp Epidemiol* 1996;17[4]:214). *Infect Control Hosp Epidemiol.* 1996; 17: 53–80
14. Siegel, JD, Rhinehart, E, Jackson, M, Chiarello, L, Health Care Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. *Am J Infect Control.* 2007; 35: S65–S164. Accessed December 12, 2023
15. Harte, JA. Standard and Transmission-Based Precautions *J Am Dent Assoc* 2010; 141(5): 572 – 581.
16. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). Potential Exposures at Work. Accessed December 12, 2023
17. Centers for Disease Prevention & Control. Infection Control and Prevention in Dental Settings. Summary of Infection Prevention Practices in Dental Settings. Accessed December 12, 2023
18. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel coronavirus in saliva [published online ahead of print, 2020 Feb 12]. *Clin Infect Dis.* 2020;ciaa149. doi:10.1093/cid/ciaa149.
19. Rodríguez-Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global - Travel and the 2019 novel coronavirus. *Travel Med Infect Dis.* 2020;33:101578. doi:10.1016/j.tmaid.2020.101578.
20. Faecher RS, Thomas JE, Bender BS. Tuberculosis: a growing concern for dentistry?. *J Am Dent Assoc.* 1993;124(1):94–104. doi:10.14219/jada.archive.1993.0003.

21. Nash KD. How infection control procedures are affecting dental practice today. *J Am Dent Assoc.* 1992;123(3):67–73. doi:10.14219/jada.archive.1992.0076.
22. Patel M. Infection control in dentistry during COVID-19 pandemic: what has changed? *Heliyon* 2020 e05402. doi:10.1016/j.heliyon.2020.e05402
23. Benzian H, Beltran-Aguilar E, Niederman R. Systemic management of pandemic risks in dental practice: A consolidated framework for COVID-19 control in dentistry. *Frontiers in Medicine.* 2021; 8: 644515.
24. Hamedani S, Farshidfar N, Ziaei A, Pakravan H. The dilemma of COVID-19 in dental practice concerning the role of saliva in transmission: a brief review of current evidence. *Eur Oral Res* 2020; 54: 92-100.
25. Gallagher JE, Johnson I, Verbeek JH, Clarkson JE, Innes N. Relevance and paucity of evidence: a dental perspective on personal protective equipment during the COVID-19 pandemic. *Br Dent J* 2020; 229: 121-124.
26. Beltran-Aguilar E, Benzian H, Niederman R. Rational perspectives on risk and certainty for dentistry during the COVID-19 pandemic. *Am J Infect Control* 2021; 49: 131-133.
27. COVID-19 Dental Services Evidence Review (CoDER) Working Group. Recommendations for the Re-Opening of Dental Services: A Rapid Review of International Sources (Version 1.3). Accessed April 25, 2023
28. Ferretti L, Weymunt C, Kendall M, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science* 2020; <https://doi.org/10.1126/science.abb6936>. Accessed December 12, 2023
29. Centers for Disease Control and Prevention. Infection Control Guidance. Accessed December 12, 2023
30. Baghizadeh FM. What dentists need to know about COVID-19. *Oral Oncol* 2020; 105: 104741.
31. United States Department of Labor. Occupational Safety and Health Administration. Dentistry Workers and Employers. Accessed December 12, 2023
32. Cheng HC, Chang YJ, Liao SR, Siewchaisakul P, Chem SLS. The impact of COVID-19 on knowledge, attitude, and infection control behaviors among dentists. *BMC Oral Health* 2021; 21: 584.
33. Estrich C, Mikkelsen M, Morrissey R, Geisinger ML, Ioannidou E, Vujicic M, Araujo MWB. Estimating COVID-19 prevalence and infection control practices among US Dentists. *J Am Dent Assoc* 2020; 151(11): 815-824.
34. Araujo MWB, Estrich CG, Mikkelsen M, Morrissey R, Harrison B, Geisinger ML, Ioannidou E, Vujicic M. COVID-19 among dentists in the United States: A 6-month longitudinal report of accumulative prevalence and incidence. *J Am Dent Assoc* 2021; 152(6): 425-433.
35. Centers for Disease Control and Prevention (CDC). Summary of Infection Prevention Practices in Dental Settings: Basic Expectations for Safe Care. Atlanta: CDC, US Department of Health and Human Services. 2016.
36. Centers for Disease Control and Prevention (CDC). Guidance for Dental Settings: Interim Infection Prevention and Control Guidance for Dental Settings During the COVID-19 Response. 2020. Accessed December 12, 2023
37. American Dental Association (ADA) What Constitutes a Dental Emergency? 2020. Accessed April 25, 2023
38. EPA. Pesticide Registration. List N: Disinfectants for Use Against SARS-CoV-2. Accessed December 12, 2023
39. Coronavirus Disease 2019 (COVID-19) | CDC. Accessed December 12, 2023
40. Ghai S. Teledentistry during COVID-19 pandemic. *Diabetes Metab Syndr* 2020; 14(5): 933-935.
41. Bahanan L, Alsharif M. Factors affecting the acceptance of teledentistry determined using the technology acceptance model: A cross-sectional study. *Digit Health* 2023; 9: 20552076231158034.
42. United States Department of Labor. Occupational Safety and Health Administration. Dentistry Workers and Employers. Accessed December 12, 2023

43. Seirafianpour F, Sodgar S, Pour Mohammad A, et al. Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review. *Dermatol Ther* 2020; e13986.
44. Mitchell MB, Workman AD, Rathi VK, Bhattacharyya N. Smell and taste loss associated with COVID-19 infection. *Laryngoscope* 2023; 133(9): 2357-2361.
45. Iranmanesh B, Khalili M, Amiri R, Zartab H, Aflatoonian M. Oral manifestations of COVID-19 disease: A review article. *Dermatol Ther* 2021; 34(1): e14578.
46. Farid H, Khan M, Jamal S, Ghafoor R. Oral manifestations of Covid-19-A literature review. *Rev Med Virol* 2022; 32(1): e2248.
47. Soares CD, Souza LL, de Carvalho MGF, Pontes HAR, Mosqueda-Taylor A, Hernandez-Guerrero JC, do Nascimento Medeiros SD, de Oliveira Sales A, Alves FA, Lopes Pinto CA, de Almeida OP. Oral Manifestations of Coronavirus Disease 2019 (COVID-19): A Comprehensive Clinicopathologic and Immunohistochemical Study. *Am J Surg Pathol* 2022; 46(4): 528-536.
48. Aragonese J, Suarez A, Algar J, Rodriguez C, Lopez-Valverde N, Aragonese JM. Oral manifestations of COVID-19: Updated systematic review with meta-analysis. *Front Med* 2021; 8: e726753.
49. Rocha BA, Souto GR, de Mattos Camargo Grossman S, et al., Viral enanthema in oral mucosa: a possible diagnostic challenge in the COVID-19 pandemic. *Oral Dis* 2020.
50. Reis VP, Bezerra AR, Maia ABP, Marques LC, Conde DC. An integrative review of oral manifestations in patients with COVID-19: signs directly related to SARS-CoV-2 infection or secondary findings? *Int J Dermatol.* 2022; 61(3): 278-290.
51. Kornman KS. Mapping the pathogenesis of periodontitis: A new look. *J Periodontol* 2008; 79(85): 1560-1568.
52. Nesse W, Abbas F, van der Ploeg I, Spijkervet FKL, Dijkstra PU, Vissink A. Periodontal inflamed surface area: quantifying inflammatory burden. *J Clin Periodontol* 2008; 35(80): 668-673.
53. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. *J Periodontol* 2001; 72(9): 1221-1227.
54. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. *Emerg Microbes Infect* 2020; 9(1): 687-690.
55. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerg Microbes Infect* 2020 9(1): 386-389.
56. Wang X, Fang X, Cia Z, et al. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients. *Research (Wash DC)* 2020; 2020: 2402961.
57. Mulchandai R, Lyngdoh T, Kakkar AK, et al. Deciphering the COVID-19 cytokine storm. *Eur J Clin Invest* 2021; 51(1): e13429.
58. Hamit ZN. A systematic review of systematic reviews on the COVID-19 pandemic. *SN Compr Clin Med* 2021; 180(9): 419-436.
59. Rajpal A, Rahimi L, Ismail-Belgi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. *J Diabetes* 2020; 12(12): 895-908.
60. Bao L, Zhang C, Dong J, et al. Oral microbiome and SARS-CoV-2; beware of lung co-infection. *Front Microbiol* 2020; 11:1840.
61. Elisetti N. Periodontal pocket and COVID-19: could there be a possible link? *Med Hypotheses* 2021; 146: 110355.
62. Genco RJ, Borgnakke WS. Risk factors for periodontal disease. *Periodontol* 2000 2013; 62: 59-94.
63. Gupta S, Hayek SS, Wang W, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US *J Am Med Assoc Inter Med* 2020; 180: 1436-1447.
64. Tamimi F, Altigani S, Sanz M. Periodontitis and coronavirus disease 2019. *Periodontol* 2000 2022; 89: 207-214.
65. Schenkein HA, Papapanou PN, Genco R, et al. Mechanisms underlying the association between periodontitis and atherosclerotic disease. *Periodontol* 2000 2020; 83(1): 90-106.
66. Kara C, Celen K, Dede FO, et al. Is periodontal disease a risk factor for developing severe COVID-19 infection? The potential role of Galectin-3 *Exp Biol Med* 2020; 245(16): 1425-1427.

67. Marouf N, Cai W, Said KN, et al. Association between periodontitis and severity of COVID-19 infection. *J Clin Periodontol* 2021; 48(4): 483-491.
68. Sirin DA, Ozelik F. The relationship between COVID-19 and the dental damage stage determined by radiological examination. *Oral Radiol* 2021; 3: 1.
69. Fernandex Matuch B, Dolhnikoff M, Maia GVA, et al. Periodontal tissues are targets for SARS-CoV-2: a post-mortem study. *J Orol Microbiol* 2020; 13(1): 1848135.
70. Basso L, Chacun D, Sy K, Gorsgogeat B, Gritsch K. Peirodental diseases and COVID-19: a scoping review. *Eur J Dent* 2021; 15(4): 768-775.
71. Gupta S, Mohindra R, Chauhan PK, et al. SARS-CoV-2 Detection in Gingival Crevicular Fluid. *Journal of Dental Research*. 2021;100(2):187-193.
72. Roganovic JR. MicroRNA-146a and -155, upregulated by periodontitis and type 2 diabetes in oral fluids, are predicted to regulate SARS-CoV-2 oral receptor genes. *J Periodontol* 2021; 92(7): 35-43.
73. Tonetti MS, Jepsen S, Jin L, et al. Impact of the global burden of periodontal disease on health, nutrition, and wellbeing of mankind: a call for global action. *J Clin Periodontol* 2017; 44(5): 456-462.
74. Sanz M, Del Castillo AM, Jepsen S, et al. Periodontitis and cardiovascular diseases. Consensus report. *Glob Heart* 2020; 15(1): 1.
75. Fine N, Chadwick JW, Sun C, et al. Periodontal inflammation primes the systemic innate immune response. *J Dent Res* 2021; 100(3): 318-325.
76. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J Clin Virol* 2020; 127: 104370.
77. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; 395: 1033-1034.
78. Kazancioglu S, Yilmaz FM, Bastug A, et al. Assessment of galectin-1, galectin-3, and PGE2 levels in patients with COVID-19 *Jpn J Infect Dis* 2021; 74(6): 530-536.
79. Masso-Silva JA, Moshensky A, Lam MTY, et al. Increased peripheral blood neutrophil activation phenotypes and neutrophil extracellular trap formation in critically ill coronavirus disease 2019 (COVID-19) patients: a case series and review of the literature. *Clinical Infectious Diseases* 2022 74(3): 479-489.
80. Sampson V, Kamona N, Sampson A, et al. Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections? *Br Dent J* 2020; 228(12): 971-978.
81. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci* 2020; 12(1): 8.
82. Botros N, Iyer P, Ojcius DM. Is there an association between oral health and severity of COVID-19 complications? *Biomed J* 2020; 43(4): 325-327.
83. Awano S, Ansai T, Takata Y, et al. Oral health and mortality risk from pneumonia in the elderly. *J Dent Res* 2008; 87(4): 334-339.
84. Aquino-Martinez R, Hernandez-Vigueras S. Severe COVID-19 lung infection in older people and periodontitis. *J Clin Med* 2021; 10(2): 279.
85. Pftzner A, Lazzara M, Jantz J, et al. Why do people with diabetes have a high risk for severe COVID-19 disease?—A dental hypothesis and possible prevention strategy. *J Diabetes Sci Technol* 2020; 14(4): 769-771.
86. Chapple ILC, Mealey BL, Van Dyke TE, et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *J Periodontol*. 2018; 89(Suppl 1): S74-S84.
87. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. *Nat Rev Dis Primers* 2017; 3: 17038.
88. Nazir MA. Prevalence of periodontal disease, its association with systemic disease and prevention. *Int J Health Sci (Qassim)* 2107; 11(2): 72-80.

89. Yang LC, Suen YJ, Wang YH, et al. The association of periodontal treatment and decreased pneumonia. *Int J Environ Res Public Health* 2020; 17(1): 356.
90. Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in an New York hospital system. *Cancer Discov* 2020; 10(7): 935-941.
91. Caballero AE, Ceriello A, Misra A, et al. COVID-19 in people living with diabetes: an international consensus. *J Diabetes Complications* 2020; 34(9): 107671.
92. Scannapieco FA, Ho AW. Potential associations between chronic respiratory disease and periodontal disease: analysis of National Health and Nutrition Examination Survey III. *J Periodontol* 2001; 72(1): 50-56.
93. Grigoriadis A, Raisanen IT, Parnanen P, Tervahartiala T, Sorsa T. Is there a link between COVID-19 and periodontal disease? A narrative review. *Eur J Dent* 2022; 16(3): 514-520.
94. Baima G, Marruganti C, Sanz M, Aimetti M, Romandini M. Periodontitis and COVID-19: Biologic Mechanisms and Meta-analysis of epidemiologic evidence. *J Dent Res* 2022; 10(12) 1430-1440.
95. Centers for Disease Control and Prevention. HPV and Oropharyngeal Cancer. Accessed December 12, 2023
96. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med* 2021. 27(4):601-615.
97. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *medRxiv* 2020; 2.020.2012.2014.20248802
98. Hur K, Choi JS, Zheng M, Shen J, Wrobel B. Association of alterations in smell and taste with depression in older adults. *Laryngoscope Invest Otolaryngol* 2018; 3: 94-99.
99. Ismail II, Gad KA. Absent blood oxygen level-dependent functional magnetic resonance imaging activation of the orbitofrontal cortex in a patient with persistent cacostmia and cacogeusia after COVID-19 infection. *JAMA Neurol* 2021. 8(5):609-610.
100. Marchesan JT, Warner BM, Byrd KM. The “oral” history of COVID-19: Primary infection, salivary transmission, and post-acute implications. *J Periodontol* 2021; 92: 1357-1367.

Additional Resources

- JADA. ADA Coronavirus Resource Center for Dentists. Accessed December 12, 2023
- CDC. Coronavirus (COVID-19). Accessed December 12, 2023
- EPA. Pesticide Registration. List N: Disinfectants for Use Against SARS-CoV-2. Accessed December 12, 2023
- ADA. ADA Coronavirus (COVID-19) Center for Dentists. Accessed December 12, 2023
- CDC. COVID-19 Community Risk Assessment County Check Tool. Accessed December 12, 2023

About the Author



Maria L. Geisinger, DDS, MS

Mia L. Geisinger, DDS, MS is a Professor and Director of Advanced Education in Periodontology in the Department of Periodontology in the University of Alabama at Birmingham (UAB) School of Dentistry. Dr. Geisinger received her BS in Biology from Duke University, her DDS from Columbia University School of Dental Medicine, and her MS and Certificate in Periodontology and Implantology from the University of Texas Health Science Center at San Antonio. Dr. Geisinger is a Diplomate in the American Board of Periodontology and a Fellow in the International Team for Implantology. She has served as the President of the American Academy of Periodontology Foundation, as the Chair of the American Dental Association's Council on Scientific Affairs, and on multiple national and regional organized dentistry committees. She currently serves as the AAP's Vice President, as a Board member for the ADA Science and Research Institute, and on numerous AAP, AADOCR and ADA committees and task forces. She has authored over 75 peer-reviewed publications and serves on the editorial and advisory boards of several publications. Her research interests include periodontal and systemic disease interaction, implant dentistry in the periodontally compromised dentition, and novel treatment strategies for oral soft and hard tissue regeneration. She lectures nationally and internationally on topics in periodontology and oral healthcare.

Email : miagdds@uab.edu